~~<i id='D1C1E35E92'><strike id='D1C1E35E92'><tt id='D1C1E35E92'><pre id='D1C1E35E92'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

leisure time

author：focus 2025-08-12 11:29:04 - browse：8719

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Vertigo drug brings hope for rare neuron disorder, Niemann

knowledge

entertainment

focus

hotspot

explore

leisure time

AlexHogan/STATForgetMcGregor-Mayweather.ThebiotechworldhasbeenwaitingformonthstohearaboutNovartis’s

WSS

The Pandemic Treaty must support building strong health systems

Let's speed up science by embracing open access publishing

Time to name cancers by genetics, not organ of origin, expert says

Biden administration opens offers in Medicare drug price negotiations

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Some dementia cases could be undiagnosed liver disease

explore

leisure time

knowledge

Activists slam private health insurers over coverage restrictions

BMI, flaws aside, is found to be useful estimate of body fat in youth

Drug repurposing or repositioning? The language matters

ASCO: Palliative care found as helpful given virtually as in person

Activists slam private health insurers over coverage restrictions

Cybersecurity threat forces Lurie Children's to take systems offline

Medicare proposal to cover medical devices draws a mixed reaction

With trial win, GSK could get blood cancer drug back on market

Medical records are filled with copy

Covid misinformation case heads to Supreme Court

entertainment

Quicker fix for pulse oximeters urged during FDA public meeting

Innovation in antibiotics is ailing. 'Brain drain' may kill it

With trial win, GSK could get blood cancer drug back on market

Cybersecurity threat forces Lurie Children's to take systems offline

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Commercial surrogacy can be ethical, despite pope’s claims

focus

hotspot

explore

leisure time